ArticleBMC microbiology2025
Oral and fecal microbiome alterations in pancreatic cancer: insights into potential diagnostic biomarkers.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Noninvasive microbiota-based diagnostic models for pancreatic ductal adenocarcinoma: a systematic review and diagnostic test accuracy meta-analysis.Frontiers in microbiology · 2026Pooled it
- Exploring the biliary microbiome in hepatopancreatobiliary disorders: a comprehensive systematic review of microbial signatures and diagnostic potential.BMC gastroenterology · 2025Pooled it
- Gastrointestinal Microbiome Dysbiosis in Cancer Development: Mechanisms and Biomarker Potential.MicrobiologyOpen · 2026Review
- Kernel Fatty Oils ofNutrients · 2026Article
- Microbiota in pancreatic cancer: Roles in tumor initiation and progression (Review).Oncology letters · 2026Review
- The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.Biomedicines · 2026Review
- Pathogenesis, Diagnostic Pathways, and New Therapeutic and Nutritional Strategies for Pancreatic Cancer-Associated Cachexia.Cancers · 2026Review
- Role of Probiotics in Enhancing Immune Function and Improving the Effectiveness of Treatments for Pancreatic Cancer.Microorganisms · 2025Review
- Gut microbiota, circulating metabolites, and pancreatic cancer risk: a multi-method causal inference study with cross-population validation.Frontiers in microbiology · 2025Article
- Oral pathogens meet the gut microbiome: new mechanistic insights on systemic disease.Frontiers in cellular and infection microbiology · 2025Review
- Machine learning and microbiome analysis for early detection of pancreatic cancer.Gastroenterology and hepatology from bed to bench · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe human microbiome plays a pivotal role in pancreatic cancer (PC). This study investigates the abundance of specific gut and oral microbes in PC patients compared to healthy controls.
methodsA cohort of 20 diagnosed PC patients and an equivalent control group were recruited. Comprehensive lifestyle data, such as overall food consumption, were collected. Saliva and stool samples were prepared. Microbial DNA was extracted from stool and saliva samples using specialized kits. Primers were designed targeting the conserved regions of the 16 S rRNA genes from Neisseria elongata, Granulicatella adiacens, Fusobacterium nucleatum, Roseburia intestinalis, and Bifidobacterium bifidum. The quantities of selected bacterial species were evaluated using real-time quantitative PCR.
resultsGranulicatella adiacens and Fusobacterium nucleatum were significantly increased in the PC group (medians: 7.35 and 4.37 log10 CFU/g, respectively) compared to controls (medians: 2.43 and 1.20 log10 CFU/g ; P < 0.001 for both). Conversely, Neisseria elongata, Roseburia intestinalis, and Bifidobacterium bifidum levels were significantly lower in PC patients (medians: 2.37, 2.34, and 3.45 log10 CFU/g, respectively) compared to controls (medians: 5.63, 5.07, and 4.34 log10 CFU/g; P < 0.001). The principal component analysis confirmed distinct clustering of microbiota profiles between the two groups, with key microorganisms associated with PC. The discriminatory performance of clinical and microbiota variables demonstrated notable accuracy in classifying PC, particularly metrics such as hemoglobin and hematocrit, achieving an area under the curve (AUC) of 1.00.
conclusionsIn summary, these findings highlight the significant association between microbiome composition and PC, underscoring the potential of microbiota profiles as non-invasive diagnostic biomarkers that warrant further investigation for early detection and therapeutic targeting in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.